Pierre Jean Guillausseau
- [Compliance and optimisation of oral antidiabetic therapy. A longitudinal study]Pierre Jean Guillausseau
Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris Université Paris 7
Presse Med 33:156-60. 2004..5 to 56.8%, and increase in percentage of once-daily dosing regimen from 12 to 58.4%...
- Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administrationPierre Jean Guillausseau
Department of Medicine B, Lariboisiere Hospital, University Paris 7 Denis Diderot, Paris, France
Treat Endocrinol 4:167-75. 2005..Therefore, optimization of treatment through a reduction in the frequency of antihyperglycemic administration could be a valuable weapon in the battle to improve health outcomes and reduce the burden of type 2 diabetes...
- Maternally inherited diabetes and deafness: a multicenter studyP J Guillausseau
Department of Medicine B, Lariboisiere Hospital, 2 rue Ambroise Pare, F75010 Paris, University Paris 7 Denis Diderot, France
Ann Intern Med 134:721-8. 2001..Maternally inherited diabetes and deafness (MIDD), which is seen in 0.5% to 2.8% of patients with type 2 diabetes mellitus, is related to a point mutation at position 3243 of mitochondrial (mt) DNA. Its clinical description is incomplete...
- [Compliance to treatment and type 2 diabetes: impact on glycemic balance]Pierre Jean Guillausseau
Presse Med 32:70. 2003
- [Urinary tract infections and diabetes mellitus]Pierre Jean Guillausseau
Service de Medecine B, Hopital Lariboisiere, 75475 Paris
Rev Prat 53:1790-6. 2003..Nosocomial UTI is frequent in such patients. Meticulous preventive measures are the best means of reducing the prevalence of UTI in diabetics...
- [Pathogenesis of type 2 diabetes mellitus]P J Guillausseau
Service de médecine interne B, Hopital Lariboisiere, 2, rue Ambroise Pare, 75475 Paris 10, France
Rev Med Interne 24:730-7. 2003..It results from aging of the population and from "western" lifestyle, with progressive increase in mean body weight, due to excess in energy intake, decreased energy expenses and low physical activity level...
- [Type II diabetes in children and adults]Pierre Jean Guillausseau
Service de Medecine B, hôpital Lariboisière et faculté de médecine Lariboisière Saint Louis, Universite Paris 7 Denis Diderot, 75475 Paris
Rev Prat 53:1463-71. 2003
- Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practiceP J Guillausseau
Service de Medecine B, Hopital Lariboisiere, Paris et Université Paris 7 Denis Diderot, France
Diabetes Metab 29:79-81. 2003..To address compliance with oral antidiabetic agents and its impact on metabolic control in type 2 diabetic patients treated in general practice...
- 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once dailyP J Guillausseau
Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris, France
Diabetes Metab 27:133-7. 2001..The present study was undertaken to assess the effect of a new formulation of gliclazide administered once daily, gliclazide modified release, on plasma glucose levels over 24 hours...
- Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistanceFranck Mauvais-Jarvis
Department of Endocrinology and Diabetes, Saint Louis Hospital and University of Paris VII School of Medicine, Paris, France
Diabetes 53:645-53. 2004....
- [Drug treatment of type 2 diabetes]Amélie Tielmans
Service de médecine interne B, AP HP, Hopital Lariboisiere, 75010 Paris, France
Presse Med 36:269-78. 2007..GLP-1 (Glucagon-Like Peptide-1) analogs and DPP-IV (dipeptidyl-peptidase-IV) inhibitors are new drug classes currently under development...
- [Drug treatment in type 2 diabetes (part 2)]Amélie Tielmans
Service de médecine interne B, AP HP, Hopital Lariboisiere, Paris
Presse Med 36:467-74. 2007..5%. New guidelines for management of type 2 diabetes were published in 2006...
- Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathyAmelie Lecleire-Collet
Departments of Ophthalmology, Hopital Fernand Widal, Assistance Publique Hopitaux de Paris, Paris 7 University, Paris, France
Invest Ophthalmol Vis Sci 52:2861-7. 2011..To correlate retinal function with vascular response to flicker light in normotensive patients with diabetes without diabetic retinopathy (DR)...
- A possible hypophosphatemia-induced, life-threatening encephalopathy in diabetic ketoacidosis: a case reportBruno Megarbane
Medical Critical Care Department, Lariboisiere Hospital, Paris, France
Am J Med Sci 333:384-6. 2007..Our data strongly suggest that phosphate depletion-induced encephalopathy probably originates from direct impairment of cerebral electrophysiological activity rather than from cardiac flow alteration...
- Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological controlBeatrix Cochand-Priollet
Department of Pathology and Cytopathology, Lariboisiere Hospital, Paris, France
Thyroid 21:1067-73. 2011..We aimed to assess the diagnostic accuracy of immunocytochemistry (ICC) of thyroid FNA to improve its sensitivity and specificity...
- Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsNish Chaturvedi
International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
Lancet 372:1394-402. 2008..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialAnne Katrin Sjølie
Department of Ophthalmology, Odense University Hospital, Odense, Denmark
Lancet 372:1385-93. 2008..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...
- PROactive studyPierre Jean Guillausseau
Lancet 367:23; author reply 26-7. 2006